ImmuPharma (LON:IMM) Trading 19.1% Higher - Should You Buy?

Key Points

• ImmuPharma plc saw its stock rise by 19.1% on Thursday, increasing from a previous close of GBX 11.50 to GBX 13.70.
• The company has a market capitalization of £68.27 million and a significantly negative P/E ratio of -1,535.06.
• ImmuPharma's lead program, P140 (Lupuzor™), is developed for treating Lupus, with potential applications for other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report) shares were up 19.1% on Thursday . The stock traded as high as GBX 14 ($0.19) and last traded at GBX 13.70 ($0.19). Approximately 20,990,227 shares were traded during trading, an increase of 146% from the average daily volume of 8,516,832 shares. The stock had previously closed at GBX 11.50 ($0.16).

ImmuPharma Stock Performance

The firm has a market capitalization of £56.23 million, a P/E ratio of -1,264.38 and a beta of 1.53. The firm has a 50 day moving average price of GBX 4.46 and a two-hundred day moving average price of GBX 3.33.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.